BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

768 related articles for article (PubMed ID: 26240504)

  • 1. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
    Woo YJ; Jang SY; Lim TH; Yoon JS
    Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between TSH receptor antibody assays and clinical manifestations of Graves' orbitopathy.
    Jang SY; Shin DY; Lee EJ; Choi YJ; Lee SY; Yoon JS
    Yonsei Med J; 2013 Jul; 54(4):1033-9. PubMed ID: 23709442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of TSH-receptor antibody levels in predicting disease course in Graves' orbitopathy: comparison of the third-generation TBII assay and Mc4-TSI bioassay.
    Jang SY; Shin DY; Lee EJ; Lee SY; Yoon JS
    Eye (Lond); 2013 Aug; 27(8):964-71. PubMed ID: 23743527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics of Graves' orbitopathy in patients showing discrepancy between levels from TBII assays and TSI bioassay.
    Jang SY; Shin DY; Lee EJ; Yoon JS
    Clin Endocrinol (Oxf); 2014 Apr; 80(4):591-7. PubMed ID: 24033537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
    Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
    J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.
    Gerding MN; van der Meer JW; Broenink M; Bakker O; Wiersinga WM; Prummel MF
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):267-71. PubMed ID: 10718823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of thyroid-stimulating immunoglobulins in graves' ophthalmopathy.
    Ponto KA; Kanitz M; Olivo PD; Pitz S; Pfeiffer N; Kahaly GJ
    Ophthalmology; 2011 Nov; 118(11):2279-85. PubMed ID: 21684605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of Thyroid-Stimulating Immunoglobulin Bioassay and Thyrotropin-Binding Inhibitory Immunoglobulin Assay for the Diagnosis of Graves' Disease in Patients With Active Thyrotoxicosis.
    Silva de Morais N; Angell TE; Ahmadi S; Alexander EK; Dos Santos Teixeira PF; Marqusee E
    Endocr Pract; 2022 May; 28(5):502-508. PubMed ID: 35091101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.
    Khoo DH; Eng PH; Ho SC; Tai ES; Morgenthaler NG; Seah LL; Fong KS; Chee SP; Choo CT; Aw SE
    Thyroid; 2000 Dec; 10(12):1093-100. PubMed ID: 11201855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy.
    Subekti I; Boedisantoso A; Moeloek ND; Waspadji S; Mansyur M
    Acta Med Indones; 2012 Apr; 44(2):114-21. PubMed ID: 22745141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.
    Nicolì F; Lanzolla G; Mantuano M; Ionni I; Mazzi B; Leo M; Sframeli A; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
    J Endocrinol Invest; 2021 Mar; 44(3):581-585. PubMed ID: 32648002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two different TSH-receptor antibody assays: A clinical practice study.
    van Balkum M; Schreurs MWJ; Visser WE; Peeters RP; Dik WA
    Heliyon; 2023 Dec; 9(12):e22468. PubMed ID: 38107298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods.
    Morris JC; Hay ID; Nelson RE; Jiang NS
    Mayo Clin Proc; 1988 Jul; 63(7):707-17. PubMed ID: 2898572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy.
    Sarić Matutinović M; Diana T; Nedeljković Beleslin B; Ćirić J; Žarković M; Kahaly GJ; Ignjatović S
    J Endocrinol Invest; 2022 Jan; 45(1):189-197. PubMed ID: 34324163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison Between Thyroid Stimulating Immunoglobulin and TSH-Receptor Antibodies in the Management of Graves' Orbitopathy.
    Khamisi S; Lundqvist M; Engström BE; Larsson A; Karlsson FA; Ljunggren Ö
    Exp Clin Endocrinol Diabetes; 2023 Apr; 131(4):236-241. PubMed ID: 36706788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.